CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
2.400
-0.040 (-1.64%)
At close: Jun 27, 2025, 4:00 PM
2.400
0.00 (0.00%)
After-hours: Jun 27, 2025, 8:00 PM EDT
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
12.32M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CVM News
- 9 days ago - FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients - Business Wire
- 5 weeks ago - CEL-SCI Announces Closing of Public Offering - Business Wire
- 5 weeks ago - CEL-SCI Announces Pricing of Public Offering - Business Wire
- 5 weeks ago - CEL-SCI Announces Proposed Public Offering - Business Wire
- 5 weeks ago - CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia - Business Wire
- 5 weeks ago - CEL-SCI Announces Combination of Common Stock - Business Wire
- 6 weeks ago - CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results - Business Wire
- 2 months ago - CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Business Wire